Connecticut Small Businesses, Biotech Push for R&D Tax Credit

Connecticut lawmakers, the Lamont administration, and industry groups are pushing for a big expansion of the state’s R&D tax credit. They want to reach small businesses and privately held pass-through entities.

The proposal, including House Bill 5319 and Senate Bill 84 in the governor’s budget, would make the credit more accessible. It’s targeted at life sciences, manufacturing, and fintech startups anchoring Connecticut’s innovation economy.

Find Your Ideal Getaway in Connecticut
Explore top-rated stays with no booking fees and instant confirmation. Your dream trip starts here!
Start Exploring Now

I’ve covered the state’s economic debates for thirty years, and honestly, this could change where startups put down roots—from Hartford to New Haven, Stamford to Bridgeport, and beyond.

Expanded R&D Credit: What Would Change

The core idea is to offer a 6% credit on R&D expenses for companies with under $70 million in gross income, starting with the 2026 tax year.

The program would cap credits at $1.5 million per company per year, with an overall annual cap of $25 million.

Any leftover credits would be partially refundable to firms with low tax liability. Biotech firms would get a larger share of the refund (90%) than other small businesses (65%).

Credit mechanics and administration

The Department of Economic and Community Development (DECD) would run the voucher program. They’d focus on oversight and making sure investment goes where it’s needed.

This setup tries to prevent leakage, but still gives startups access to cash relief—especially when federal funding dries up or acquisition milestones are close.

Credit rate: 6% of qualifying R&D expenses.
Eligibility: Under $70 million in gross income.
Company cap: $1.5 million per year per company.
Program cap: $25 million annually statewide.
Refundable portion: Leftover credits partially refundable, with priority for low-tax firms and biotech sectors.
Biotech preference: 90% refund share for biotech firms; 65% for other small businesses.

Who would benefit?

The plan is meant to help small, early-stage life sciences firms that rely on federal funding and potential acquisitions. It should keep companies rooted in Connecticut.

Startups operating in biotech clusters along the I-95 corridor and inland would benefit most. Fintech and advanced manufacturing firms could also get a cushion to expand R&D programs.

Why It Matters for Connecticut Towns

From Hartford to New Haven, Stamford to Bridgeport, and Waterbury to Norwalk, these credits could shape where founders decide to locate, grow, or pivot.

Cities like Danbury, Greenwich, Milford, Middletown, New Britain, Bristol, Groton, East Hartford, and Manchester might see stronger retention of R&D jobs and more investment in early-stage science.

Local leaders see the credits as a way to diversify economies and attract venture capital. They hope it’ll strengthen ties between universities, hospitals, and industry partners.

The ripple effects could reach a wide range of Connecticut communities, from small towns in Litchfield County to coastal cities in New London County.

Hartford could see more biotech pilots tied to university research and hospital partnerships.
New Haven’s life sciences ecosystem might use credits to keep startups during tough federal grant cycles.
Stamford and Bridgeport could become more attractive for fintech R&D and advanced manufacturing labs.
Waterbury and Norwalk might host mixed-use facilities blending product development with manufacturing scale-up.
Danbury and Greenwich would benefit from their proximity to major metro corridors while nurturing smaller, high-innovation firms.

Support and Skepticism

The measure has broad backing in the legislature and among industry groups, including BioCT. They argue the credits are vital for early-stage life sciences firms that lean on federal funding and possible acquisitions to stay afloat.

Proponents say expanding credits would broaden Connecticut’s innovation pipeline and help key sectors compete with neighboring states that offer generous incentives.

Supporters’ view

“This is about keeping Connecticut competitive for startups and life sciences jobs,” one industry advocate told me.

“We need a stable, scalable program that rewards real R&D investment and job creation.”

Critics’ concerns

Some researchers and fiscal watchdogs warn that R&D tax credits have mixed evidence on effectiveness. They emphasize the need for careful targeting, rigorous evaluation, and fiscal caps.

Lawmakers will have to decide if credits spark new activity or just subsidize what’s already happening, and how much the state should steer investment versus letting the market do its thing.

What’s Next in Hartford

After years of failed attempts to extend R&D credits to pass-through entities, this session feels different. There’s a renewed push, and honestly, the legislative backing looks broader than it’s been in a long while.

Success will depend on how lawmakers define eligibility, set caps, and handle enforcement. They’ll also need to show real results—more jobs, more capital investment, and a stronger long-term outlook for Connecticut’s competitiveness.

If it goes through, the program might start with the 2026 tax year. DECD would take the lead on evaluation and reporting, aiming for accountability and transparency, though we all know how tricky that can get in practice.

Here is the source article for this story: CT small businesses hope their latest R&D tax credit push pays off

Discover Your Perfect Stay in Connecticut
Find available hotels and vacation homes instantly. No fees, best rates guaranteed!
Check Availability Now